Introduction
Most infections respond favourably to a single antimicrobial agent. There are infections, however, for which therapy with combination of agents may be advantageous, such as those caused by resistant organisms, those where current therapy is suboptimal or toxic to patients, and those affecting patients with abnormal host defence systems. Infection due to Fusarium, a fungus that is increasingly recognized as a significant human pathogen, is such an example, since it is generally refractory to currently available antifungal agents, carries a high mortality, and has a predilection for severely immunocompromised hosts.
Tetracycline, a protein synthesis inhibitor, possesses no intrinsic antifungal activity, but synergy with amphotericin B has been demonstrated in vitro and in animal models. 1, 2 Azithromycin also acts by inhibiting protein synthesis, and an advantage of azithromycin is that good tissue levels can be achieved. 3 We therefore investigated the in-vitro interaction between amphotericin B and azithromycin against 26 clinicalisolates of Fusarium.
Materials and methods
Twenty-six clinical isolates of Fusarium obtained from the clinical microbiology laboratory at the Shands Teaching Hospital, Gainesville, FL, USA, or the Fungus Testing Laboratory, University of Texas Health Science Center, San Antonio, TX, USA, were investigated. MICs were determined by broth macrodilution. 4 A two-dimensional chequerboard macrodilution method was performed to characterize the interaction between amphotericin B and azithromycin. 5 Aliquots of 50 uL amphotericin B (Bristol-Myers Squibb, Princeton, NJ, USA) and azithromycin (Pfizer Central Research, Groton, CT, USA) at concentrations 20 times the final concentrations were dispensed into 12 mm 75 mm polystyrene tubes. In the case of single-drug controls, 50 uL sterile water was dispensed along with 50 uL of drug. Final test concentrations ranged from 0.03 to 16 mg/L for amphotericin B and 0.25 to 128 mg/L for azithromycin.
Conidia were counted using a haemocytometer, then diluted 1:10 with RPMI 1640 medium (American Biorganics, Inc., Niagara Falls, NY, USA) with L-glutamine, without bicarbonate, and buffered at pH 7.0 with 0.165 M morpholinepropane-sulphonic acid (MOPS) to attain a final inoculum concentration of 1 10 4 to 5 10 4 cfu/mL. Nine hundred microlitres of inoculum were added to the tubes containing drugs. Tubes were incubated at 35°C, and readings taken after 24 and 48 h.
The minimum lethal concentration (MLC) was determined by plating 100 uL from each tube with no visible growth on to Sabouraud agar plates, which were then incubated at 35°C. The MLC was defined as the lowest concentration of each drug yielding 5 colonies after 48 h of incubation. Synergy was defined as greater than two-fold reduction in MICs and MLCs of both drugs when tested in combination compared to respective MICs and MLCs when tested alone.
Colony counts were performed using an isolate of Fusarium solani (isolate no. 96-2552). After reading 48-h MICs, serial ten-fold dilutions were performed on tubes containing drug-free control, amphotericin B at a concentration of 0.25 mg/L (four-fold lower than MIC), azithromycin at concentrations of 0.25 to 64 mg/L, and combinations of amphotericin B at 0.25 mg/L with all concentrations of azithromycin. Inocula of 100 uL from the original tubes and all tubes containing ten-fold diluted suspensions were dispensed on to Sabouraud dextrose agar plates. Plates were incubated at 35°C for 48 h, and colonies were counted. The cfu/mL was calculated and expressed as the mean of counts at all dilutions where growth was evident. Our in-vitro data (see Table) support the clinical experience that Fusarium is often refractory to amphotericin B. Indeed, 85% (22/26) of Fusarium isolates tested exhibited amphotericin B MICs 1 mg/L; the MLCs exhibited by each isolate were within two-fold dilution of respective MICs. These levels are not reliably achieved in serum with the present dosage regimens of amphotericin B. This is an ominous finding, since Fusarium spp. have also demonstrated in-vitro resistance to other antifungal agents such as itraconazole and flucytosine. 6 We have demonstrated that, upon combination with azithromycin, amphotericin B MICs were reduced by a mean of 3.2-fold (range: two-fold to four-fold) (see Table) . More importantly, the combination with azithromycin enhanced the antifungal effect of amphotericin B by reducing amphotericin B MICs from relatively resistant levels (mean MIC of 1 mg/L) to levels that can be easily achieved in serum (mean MIC of 0.37 mg/L) (see Table) . Among the 22 isolates that exhibited amphotericin B MICs 1 mg/L, nine had their MICs reduced to 0.25 mg/L, 12 to 0.5 mg/L, and one to 1 mg/L. The synergy between amphotericin B and azithromycin against all isolates of Fusarium highlights one of the primary goals of combination therapy: the potentiation of the antimicrobial activity of each individual agent upon combination against resistant organisms.
Synergy between amphotericin B and azithromycin was further evident from our colony count experiment (Figure) . The MICs and MLCs of amphotericin B and azithromycin against this isolate were 1 mg/L and 128 mg/L, respectively. The colony counts of the isolate were essentially identical for drug-free control, amphotericin B at a concentration of 0.25 mg/L (a concentration four-fold less than the amphotericin B MIC and MLC), and azithromycin at concentrations of 2 to 32 mg/L. When 0.25 mg/L amphotericin B was combined with 2 mg/L azithromycin (a concentration 128-fold less than the azithromycin MIC and MLC), a 54% reduction in cfu/mL was noted (0.4-log reduction). Further reductions in cfu/mL of 80%, 86%, and 96% were demonstrated when 0.25 mg/L amphotericin B was combined with increasing azithromycin concentrations of 4 mg/L, 16 mg/L, and 32 mg/L, respectively.
In addition to increasing the effectiveness of amphotericin B, drug combination enabled azithromycin, which had no intrinsic antifungal activity, to exert an antifungal effect. All Fusarium isolates exhibited azithromycin MICs of 128 mg/L when tested alone. Upon combination with amphotericin B, however, the geometric mean MIC of azithromycin was reduced to 5.5 mg/L, a level that can be readily achieved in tissues (see Table) . 3 The mechanism of synergy between amphotericin B and azithromycin is unclear. We hypothesize that azithromycin has no inherent antifungal activity, owing to its inability to penetrate the fungal cell membrane. Amphotericin B, by damaging the fungal cell membrane, may facilitate the entry of azithromycin into cells; once inside cells, azithromycin can exert its antimicrobial effect by inhibiting protein synthesis. Since each drug has a distinct site and mechanism of action, synergy between the two is plausible.
In conclusion, the combination of amphotericin B and azithromycin proved superior to either agent alone against Fusarium spp. in vitro. Synergy may prove to be important in therapy against infection with Fusarium, since these organisms are often resistant to currently available antifungal agents. Furthermore, by reducing the level of amphotericin B required to inhibit Fusarium, combination regimens might permit lower doses to be used effectively, thereby reducing dose-related toxicity. In-vivo evaluation is indicated to explore further the potential role of amphotericin B-azithromycin combination therapy against fusariosis. 
